Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-10T14:32:11.307Z Has data issue: false hasContentIssue false
  • English
  • Français

A comparative review of the potential role of adenovirus and Herpes Simplex Virus in the treatment of advanced squamous cell carcinoma of the head and neck

Published online by Cambridge University Press:  01 September 2009

Stuart McCaighy
Stuart McCaighy*
Affiliation:
Radiotherapy Department, The Royal Marsden NHS Foundation Trust, London, UK
*
Correspondence to: Stuart McCaighy. Radiotherapy Department, The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK. E-mail: stuartmccaighy@yahoo.co.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

The unsatisfactory outcome of patients who receive intensive multimodality treatment for advanced squamous cell carcinoma of the head and neck (SCCHN) has motivated investigators to seek novel treatments to improve survival. Advances in molecular biology has led to the development of cancer gene therapy (CGT) and revived interest in viral vectors as a mechanism. SCCHN is an ideal model for CGT as disease remains locoregional and is amenable to injection of viruses. Adenovirus and Herpes Simplex Virus Type-1 (HSV) are the most studied Oncolytic Viruses (OVs). Both viruses have been shown to select and replicate in tumour cells and demonstrate anti-tumour effect in laboratory studies and clinical trials. Toxicity from OVs is minor and manageable. Different adenoviral mutants have been investigated with mixed responses. One vector, H101, has now been licensed after showing significant tumour regression in conjunction with chemotherapy. HSV has a larger capacity to carry genetic material and with the addition of the granulocyte–macrophage colony–stimulating factor, has the potential to stimulate an immune response systemically and at the site of disease. OVs are limited by the distribution of virus beyond injection site and by pre-existing or rapidly established immune response. Phase III studies are required.

Keywords

AdenovirusCancer gene therapyHead & neck cancerHerpes simplex virus
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 8 , Issue 3 , September 2009 , pp. 147 - 155
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wong, RJ, Kim, SH, Joe, JK, Shah, JP, Johnson, PA, Fong, Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. Am J Surg 2001; 193: 12–21.Google Scholar
Ganly, I, Soutar, DS, Kaye, SB. Current role of gene therapy in head and neck cancer. Eur J Surg Oncol 2000; 26: 338–343.Google Scholar
Cho, YH, Lee, SH, Kim, DW et al. Long term survival of respectable subset after induction chemotherapy in patients with locally advanced head and neck cancer. Head Neck 2008; 30: 246–350.CrossRefGoogle Scholar
Chisholm, E, Bapat, U, Chisolm, C, Alusi, G, Vassaux, G. Gene therapy in head and neck cancer: a review Postgrad Med J 2007; 83: 731–737.CrossRefGoogle ScholarPubMed
Seiwert, TY, Cohen, EEW, Haraf, DJ et al. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest 2007; 25: 435–444.Google Scholar
Forastiere, AA. Is there a new role for induction chemotherapy in the treatment of head and neck cancer? J Nat Canc Insti 2004; 96 (22): 1647–1649.CrossRefGoogle Scholar
Rocco, JW, Daqing, L, Liggett, WH et al. p16INK4A Adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Canc Res 1998; 4: 1697–1704.Google ScholarPubMed
Khuri, FR, Neumunaitis, J, Ganly, I et al. A Controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6 (8): 879–885.CrossRefGoogle ScholarPubMed
Harrington, KJ, Nutting, CM, Pandha, HS. Gene therapy for head and neck cancer. Cancer and Metastasis Rev 2005; 24: 147–164.Google Scholar
Young, LS, Searle, PF, Onion, D, Mautner, V. Viral gene therapy strategies: from basic science to clinical application. J Path. 2006; 208: 299–318.CrossRefGoogle ScholarPubMed
Lou, E. Oncolytic herpes virus as a potential mechanism for cancer therapy. Acta Oncol 2003; 42 (7): 660–671.CrossRefGoogle ScholarPubMed
Relph, K, Harrington, K, Pandha, H. Recent developments and current status of gene therapy using viral vectors in the United Kingdom. Br Med J 2004; 329: 839–842.CrossRefGoogle ScholarPubMed
Kirn, D, Maruza, RL, Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future decisions. Nat Med 2001; 7 7: 781–787.Google Scholar
Harrington, K, Hardev, P, Vile, R (ed). Viral Therapy of Cancer. Chapter 1. Wiley & Sons Ltd, 2008, 1–17.Google Scholar
Ganly, I, Kirn, D, Eckhardt, SG et al. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Canc Res 2000; 6: 798–806.Google ScholarPubMed
Clayman, GL, EL-Naggar, AK, Roth, JA et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck carcinoma. Cancer Res 1995; 55: 1–6.Google Scholar
Heise, C, Hermiston, T, Johnson, L et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6 (10): 1134–1139.Google Scholar
Lalonde, ES, Beyer, G, Friedlander, PL, Kolls, JK. Efficacy of transfection rates on head and neck squamous cell cancer by a novel adenovirus: an in vivo and in vitro study. Head Neck 2002; 24: 1038–1046.CrossRefGoogle ScholarPubMed
Xia, ZJ, Chang, L, Jiang, WQ et al. Phase III randomised clinical trial of intratumoural injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004; 23: 1666–1670.Google ScholarPubMed
Cheong, SC, Wang, Y, Meng, JH et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumour models. Cancer Gene Ther 2008; 15: 40–50.CrossRefGoogle Scholar
Advani, SJ. Revolt: radiation enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006; 66 3: 637–646.CrossRefGoogle ScholarPubMed
Wang, Y, Hallden, G, Hill, R et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumour models. Nat Biotech 2003; 21 (11): 1328–1335.Google Scholar
Guo, ZS, Thorne, SH, Bartlett, D. Oncolytic virotherapy: molecular targets in tumour selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim et Biophys acta doi:10.1016/j.bcan.2008.02.001Google Scholar
Harrington, K, Hardev, P, Vile, R (ed). Viral Therapy of Cancer. Chapter 2. Wiley & Sons Ltd, 2008, 19–53.Google Scholar
Harrington, K, Hardev, P, Vile, R (ed). Viral Therapy of Cancer. Chapter 3. Wiley & Sons Ltd, 2008, 117–137.Google Scholar
Fujimoto, Y, Mizuno, T, Sugiura, S et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Oto-Laryn 2006; 126: 1115–1117.Google Scholar
Hu, JCC, Coffin, RS, Davis, CJ et al. A Phase 1 study of oncoVEX GM-CSF, a second generation oncolytic Herpes simplex virus expressing granulocyte macrophage colony stimulating factor. Clin Canc Res 2006; 12 22: 6738–6747.Google Scholar
Aghi, M, Rabkin, S, Martuza, RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Nat Cancer Insti 2006; 98 1: 38–50.Google Scholar
Personal Communication with Principal investigator 17.04.08.Google Scholar